By GR-CIS | April 03, 2020 – GR-CIS, a scientifically backed Regulatory service organization actively advise stakeholders on potentials COVID-19 vaccines and treatment studies. The organization has also taken significant steps over the past few months to ensure that the organizations’s existing structure continue as possible in this challenging environment.
This challenging environment has forced GR-CIS teams to swiftly adapt and apply learnings to trials in other locations as pandemic spread brings new challenges to ongoing clinical trials.
GRCIS is deeply committed to driving research into COVID-19 and our experts are currently advising sponsors and industry stakeholders on swift, safe and efficient conduct of potential and treatment studies for COVID-19. GR-CIS expert also supporting companies for Registration and Importing new Diagnostic devices in India.
In response of the COVID-19 outbreak, many Regulatory agencies has intervene to counter the spread of the disease. For their part, regulatory bodies have taken steps to ease import restrictions and expedite registration processes for needed goods, seeking to ensure that regulations do not block the development or supply of devices that could save lives.
We continue to assess the ever-changing impact of COVID-19 on our operations and we are committed to keeping clients regularly updated on the latest developments.
